A Phase 2 Study of Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Enasidenib (Primary) ; Rituximab (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 07 Jan 2025 New trial record